Sugi Predict

Sugi Predict / Compounds / SCHEMBL4910885

SCHEMBL4910885

SCHEMBL4910885

O=C(NCl)c1cccc(F)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 1/20 0.69
▸ HDAC6 Q9UBN7 1/20 0.69
▸ CES2 O00748 1/20 0.61
▸ CES1 P23141 1/20 0.61
▸ MEN1 O00255 3/20 0.59
▸ KMT2A Q03164 3/20 0.59
▸ KCNK3 O14649 2/20 0.57
▸ PARP1 P09874 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ KCNQ3 O43525 2/20 0.55
▸ KCNQ2 O43526 2/20 0.55
▸ KCNQ5 Q9NR82 1/20 0.55
▸ NPC1 O15118 5/20 0.54
▸ RAB9A P51151 5/20 0.54
▸ KDM4E B2RXH2 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ CASP3 P42574 1/20 0.53
▸ SENP7 Q9BQF6 1/20 0.53
▸ SENP6 Q9GZR1 1/20 0.53
▸ GRM5 P41594 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11875152 0.85 HDAC6 (0.52) HDAC1HDAC6MEN1KMT2AL3MBTL1
SCHEMBL30986828 0.82 HDAC6 (1.00) HDAC1HDAC6CES2CES1MEN1
SCHEMBL28885353 0.82 HDAC6 (1.00) HDAC1HDAC6CES2CES1MEN1
SCHEMBL29379935 0.82 HDAC6 (1.00) HDAC1HDAC6CES2CES1MEN1
SCHEMBL30046370 0.80 HDAC1 (0.69) HDAC1HDAC6CES2CES1MEN1
SCHEMBL29584617 0.80 HDAC6 (0.69) HDAC1HDAC6CES2CES1MEN1
SCHEMBL405785 0.80 HDAC1 (0.69) HDAC1HDAC6CES2CES1MEN1
SCHEMBL1507076 0.80 HDAC6 (0.69) HDAC1HDAC6CES2CES1MEN1
SCHEMBL31325158 0.80 HDAC1 (0.69) HDAC1HDAC6CES2CES1MEN1
SCHEMBL2222999 0.80 HDAC1 (0.69) HDAC1HDAC6CES2CES1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110372538-A The synthetic method of one kind 2,6- dichloro-3-fluorobenzonitrile 浙江林江化工股份有限公司 2019-10-25 — — CN claimed
CN-104245675-B Cyclic amides as MetAP-2 inhibitors 默克专利股份公司 2017-10-13 — — CN claimed
CN-104744305-A Synthesis method of 2,4-dichloro-3-cyan-5-fluorobenzoic acid ZHEJIANG ZHONGXIN CHEMICALS CO LTD 2015-07-01 — — CN claimed
CN-102531961-B Preparation method of 2,6-dichloro-3-fluorobenzonitrile UNIV ZHEJIANG TECHNOLOGY 2014-06-11 — — CN claimed
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS PHARMA AG (CH) 2024-11-21 — — US disclosed
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors NOVARTIS AG (CH) 2024-09-10 — — US disclosed
CN-110372538-A The synthetic method of one kind 2,6- dichloro-3-fluorobenzonitrile 浙江林江化工股份有限公司 2019-10-25 — — CN disclosed
CN-110372538-A The synthetic method of one kind 2,6- dichloro-3-fluorobenzonitrile 浙江林江化工股份有限公司 2019-10-25 — — CN disclosed
CN-110366550-A Benzoisothiazole, isothiazolo [3,4-b ] pyridine, quinazoline, phthalazine, pyrido [2,3-d ] pyridazine and pyrido [2,3-d ] pyrimidine derivatives as KRAS G12C inhibitors for the treatment of lung, pancreatic or colorectal cancer 美国安进公司 2019-10-22 — — CN disclosed
CN-108289886-A Ion channel inhibiting compound, pharmaceutical preparation and purposes 安华赛公司 2018-07-17 — — CN disclosed
CN-104245675-B Cyclic amides as MetAP-2 inhibitors 默克专利股份公司 2017-10-13 — — CN disclosed
EP-3177603-A1 PYRROLIDINONE DERIVATIVES AS METAP-2 INHIBITORS Merck Patent GmbH (DE) 2017-06-14 — — EP disclosed
WO-2013149704-A1 CYCLIC AMIDES AS METAP-2 INHIBITORS MERCK PATENT GMBH (DE) 2013-10-10 — — WO disclosed
EP-2627631-A1 PYRROLIDINONES AS METAP2 INHIBITORS Merck Patent GmbH (DE) 2013-08-21 — — EP disclosed
CN-103153951-A Pyrrolidones as MetAP-2 inhibitors MERCK PATENT GMBH 2013-06-12 — — CN disclosed
CN-102531961-A Preparation method of 2,6-dichloro-3-fluorobenzonitrile UNIV ZHEJIANG TECHNOLOGY 2012-07-04 — — CN disclosed
WO-2012048775-A1 PYRROLIDINONES AS METAP2 INHIBITORS MERCK PATENT GMBH (DE) 2012-04-19 — — WO disclosed
CN-100556889-C N-replaces-2,4-two chloro-5-fluorobenzamides and preparation thereof and application UNIV ZHEJIANG TECHNOLOGY (CN) 2009-11-04 — — CN disclosed
US-20080051419-A1 AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. 2008-02-28 — — US disclosed
CN-101033198-A Compound of N-substituted-2,4-dichloro-5-fluorobenzamide, preparation and application thereof UNIV ZHEJIANG TECHNOLOGY (CN) 2007-09-12 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors YAP1, TEAD3, TEAD2 HDAC1 1070/4885HDAC6 231/4885CES2 4433/4885
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS YAP1, TEAD3, TEAD2 HDAC1 1070/4885HDAC6 231/4885CES2 4433/4885
US-20080051419-A1 AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS CCNY, CCND2, CCND1 HDAC1 630/4885HDAC6 589/4885CES2 3211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.